Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial I
about
The stuttering progress of cell therapy for heart diseaseInhibition of miR-302 Suppresses Hypoxia-Reoxygenation-Induced H9c2 Cardiomyocyte Death by Regulating Mcl-1 ExpressionEarly Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Stem cell therapy for cardiac dysfunctionA systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunctionAtherogenic Cytokines Regulate VEGF-A-Induced Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Endothelial Cells.Examination of the potential association of stress with morbidity and mortality outcomes in patient with heart failure.A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Prognostic value of early in-hospital glycemic excursion in elderly patients with acute myocardial infarctionLipid-lowering therapy and outcomes in heart failure.Treating the right patient at the right time: access to heart failure care.Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.Clinical effects of hypertension on the mortality of patients with acute myocardial infarction.Review of the treatment of acute coronary syndrome in elderly patients.Candesartan: widening indications for this angiotensin II receptor blocker?Single-pill combination of amlodipine and valsartan in the management of hypertension.Primary reperfusion in acute right ventricular infarction: An observational study.Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction)Heart failure in the elderly: advances and challenges.Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.Medication management of chronic heart failure in older adults.Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, EuropeaAntithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary syndrome.Death messengersAssessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs.Attenuation of miR-34a protects cardiomyocytes against hypoxic stress through maintenance of glycolysis.Molecular signature of progenitor cells isolated from young and adult human hearts.
P2860
Q28247457-4B10EBF3-59E0-4E30-AA75-D5651E0FC754Q33604736-1C90B192-0242-4BBB-8A68-53F4629B7E5AQ33663925-FDE365F9-3C13-42DD-BEF4-F77DE5762064Q33783689-D2713EF3-4284-4DD2-ADD7-7C6EECB3AA56Q34129904-FF9D9255-B518-4CA7-A4AB-E3BF7D87797DQ35627561-D203E3BC-FD40-4B04-8453-D69C99B3125AQ35729854-CE863BFD-DEB3-4788-9007-074057A0B553Q35911866-3EBD52CB-42BA-499C-94F0-23A236008F12Q36363183-B3B40384-99B2-4CBC-A745-4AABAF9D32E4Q36716493-DC1B6A89-45F6-43A4-94CD-0FB39CCD651EQ36818242-FFBA46A9-CF2E-4580-BDD0-A9DB49BDB576Q36921035-9A008D73-F40F-4BAE-8C18-CD348B34236DQ36985305-01F551B8-5249-4B4B-ACA6-7FC2139A4960Q37364497-B2B843E2-EFF0-4C46-B890-43C3C449B241Q37448924-EF9C715F-C6CB-4A5C-8D4A-0AAA804923A1Q37534746-D449B695-379D-42D4-A005-9E7FFF4CDAF9Q37552939-4BD3060B-AEF1-4130-9F6A-EE64E5E0146BQ37575996-AE086D41-CDBA-45E2-B7B8-A3CCBE379898Q37625636-C10617A0-3C61-4C56-BA98-7E5B79FD03A2Q37744960-0A7BA8C7-0B17-4467-B29D-5D56C5DC50AEQ37781702-B971C3DD-A7D1-4812-ABE0-EA4F0C3C424CQ38048843-07B8AEB4-EB34-4228-8D28-F02E16205A0DQ38126374-02EC5A4D-074F-47D2-9F60-978888933C39Q38639505-E861D766-2FD2-4DEB-B26F-A64775FB383BQ39599579-7852C7D7-54EC-4AD3-87F6-1AB2859D7AA7Q39601105-C1FFD373-5DD8-4053-B8CD-C7C4FCE5210AQ41265453-C2814069-0E7E-4ADC-8207-53A072221E00Q42860636-995B2F57-4D51-451C-B4C0-F299AC74E03BQ43430988-81AFA07C-F386-4878-83B0-7BEF567C392DQ45263919-5297F4B9-A281-43E4-8FF7-7B33E4CF93D7Q46040626-F955592D-9FE7-4296-8230-9A7D881C29ACQ47118834-FDF13534-1E67-4686-96AE-40CA928B9B92Q55365025-CA055DDE-017C-431C-8B2B-0689BBE88868
P2860
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial I
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mortality and morbidity remain ...... alsartan in Acute Myocardial I
@nl
type
label
Mortality and morbidity remain ...... alsartan in Acute Myocardial I
@nl
prefLabel
Mortality and morbidity remain ...... alsartan in Acute Myocardial I
@nl
P2093
P50
P1433
P1476
Mortality and morbidity remain ...... ial Infarction Trial (VALIANT)
@en
P2093
Anthony J Dalby
Harvey D White
John J V McMurray
José Antonio Marin-Neto
Marc A Pfeffer
Philip E G Aylward
Rolf O Nordlander
Ståle Barvik
W Douglas Weaver
P304
P356
10.1161/CIRCULATIONAHA.105.551143
P407
P577
2005-11-29T00:00:00Z